SurgOnc Today®

This podcast was recorded on September 30, which is the National Day for Truth and Reconciliation in Canada and features an interview with Dr. Nadine Caron, who was the first Indigenous female surgeon in Canada. Dr. Caron shares her experience and perspectives from her leadership roles in health equity for First Nations peoples in Northern British Columbia with Dr. Cord Sturgeon and Dr. Masha Javid. The conversation explores the inequities in cancer care and cancer outcomes among Indigenous Peoples. Cancer incidence and survival among Indigenous People, gaps in knowledge, drivers of inequity, and a path forward for developing trust are discussed.

In this inaugural episode of the Surgical Oncology Insight series of SurgOnc Today®, Dr. Shishir Maithel, Editor of Surgical Oncology Insight, SSO's open-access journal, discusses with Dr. Brett Ecker the results of a systematic review and meta-analysis characterizing the incidence of cfDNA-positivity after resection of colorectal cancer liver metastases  with quantification of its sensitivity and specificity for postoperative recurrence, as reported in his article, "The Prognostic Role of Post-operative cfDNA after Resection of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis."

The surgical management of superficial soft tissue sarcoma require a multidisciplinary surgical team given the defect and reconstruction required from an extended resection to achieve negative margins. This team most often includes the primary surgeon (surgical oncology or orthopedic oncology) and a plastic surgeon.  A critical decision in the treatment plan is whether or not to reconstruct immediately at the index operation or delay final reconstruction pending pathologic assessment of margins.  In this podcast, we will focus on the multidisciplinary surgical approach for superficial sarcoma. We will highlight the role of delayed reconstruction and key clinical considerations in this approach. 

Please listen in as Drs. Piltin, van Akkooi, and Hyngstrom discuss relevant clinical trial presentations from ASCO 2024 annual meeting and their impressions on the implications for surgical oncologists. Abstracts results discussed include the neoadjuvant NADINA and PIVOTAL trials as well as an initial report on upfront TIL therapy for stage IV patients.